LEP and type 2 diabetes mellitus: Exposure of human islets to glucose, leptin, or free fatty acids (FFA) increases the production and release of IL-1β, hence, therapy targeting IL-1β is a logical choice in protecting the beta-cell in type 2 diabetes [32].